Memo Therapeutics

Executive Summary

Memo Therapeutics AG is a late-stage Swiss biotech company leveraging its unique antibody discovery platform to develop superior therapeutics for viral infections and cancer. Founded in 2012 and headquartered in Schlieren, the company has advanced its lead candidate, potravitug, into Phase II clinical trials for the treatment of BK polyomavirus infection in kidney transplant recipients. BK polyomavirus is a significant unmet medical need, causing nephropathy and graft loss in up to 10% of renal transplant patients, with no approved therapies. Potravitug is a fully human monoclonal antibody that neutralizes the virus, offering a targeted approach to reduce viral load and prevent graft rejection. The company's platform is based on capturing rare, potent human antibody responses, positioning it to address other viral and oncology indications. As a private, late-stage company, Memo Therapeutics is poised for potential value inflection pending clinical data and strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase II data readout for potravitug in BK polyomavirus70% success
• H2 2026Potential partnership or licensing deal for BK virus program40% success
• Q1 2027Initiation of Phase I/II study in second indication30% success